Health Logic Interactive Inc · TSXV:CHIP.H
Health Logic Interactive — Investor Presentation (June 2021)
25 slides from Health Logic Interactive's investor presentation, June 2021
Slide 1: Corporate Presentation June 2021
CORPORATE PRESENTATION JUNE 2021 For information purposes only.
Slide 2: Disclaimer
DISCLAIMER Cautionary Statement The information contained in this presentation has been prepared by Health Logic Interactive Inc. (“Health Logic” or the “Company”) and contains confidential information pertaining to the business and operations of the Company and its affiliates. The information conta
Slide 3: Executive Summary
EXECUTIVE SUMMARY • EXPERIENCED, RESULTS-DRIVEN MANAGEMENT TEAM, CLINICAL TEAM, AND SCIENTIFIC ADVISORY BOARD • POTENTIALLY DISRUPTIVE POINT-OF-CARE (POC) DIAGNOSTIC TECHNOLOGY AND DATA MANAGEMENT PLATFORM FOR CHRONIC KIDNEY DISEASE (SUBJECT TO OBTAINING FDA APPROVAL)* • ~$120 BILLION SPENT PER YEAR
Slide 4: About Us
ABOUT US PUBLIC PARENT COMPANY Developing Lab-On-Chip Medical Devices We bring the lab to the home OPERATING CKD SUBSIDIARY We are a TSX Venture (TSXV:CHIP.H) public company that intends to advance and commercialize a novel medical device for Chronic Kidney Disease through our operating subsidiary M
Slide 5: Digital Medicine: The Next Trillion Dollar Industry
DIGITAL MEDICINE: The Next Trillion Dollar Industry “The Dawn of Digital Medicine,” The Economist, Dec. 03, 2020. https://www.economist.com/business/2020/12/02/the-dawn-of-digital-medicine. Potential Point-of-Care Market Size:* POINT-OF-CARE ▪ Diagnostic results at home or in the clinic $46.7B The g
Slide 6: Our Market
OUR MARKET* CHRONIC KIDNEY 80 Million AT RISK DISEASE (CKD) Diabetes and high blood pressure accounts for roughly 70% of all CKD cases. (6) 37 Million HAVE CKD American adults (roughly every 1 in 10) are Common estimated to have CKD. It is the 9th leading cause of death in the U.S. (5) Costly $120 B
Slide 7: The Problems
THE PROBLEMS CKD TESTING & DISEASE MANAGEMENT Early detection is the key to prevent progression to (7) Kidney failure and dialysis. (6) Current laboratory tests are outdated, slow, expensive and hard to access. <50% of patients at risk have been tested (5) Existing point-of-care (dipstick) test does
Slide 8: Our Technology
OUR TECHNOLOGY A PROPRIETARY LAB-ON-CHIP TECHNOLOGY CLINICALLY VALIDATED AND PATENT PENDING FOR CKD ASSESSMENT PATENT PENDING TECHNOLOGY • Multi-use*, patent pending, lab-on-chip platform technology A patent on the UAL-Chip was submitted September 24, 2019. The patent is currently • Successful proof
Slide 9: Clinical Trial Validation
CLINICAL TRIAL VALIDATION LAB EQUIVALENT RESULTS AVAILABLE AT POINT-OF-CARE The UAL-Chip measurements agree with the lab measurements. 3000 An r = 1.00 means a perfect UAL-Chip result (µg/ml) correlation. UAL-Chip vs lab measurement: 2000 99% correlated supported with a cohort of 12 people in a clin
Slide 10: Device Pipeline
DEVICE PIPELINE 1st Generation 2nd Generation We will be seeking FDA 510(K) Accelerated Approval We will be seeking FDA 510(K) Accelerated Approval Expected Approval by FDA Q3 2022* Expected Approval by FDA Q4 2023* ● For care provider use in and outside the clinic. All the features of MATLOC 1, PLU
Slide 11: Measurement of ACR and GFR test steps
MEASUREMENT OF ACR: ALBUMIN TO CREATININE RATIO IN URINE MEASUREMENT OF GFR: GLOMERULAR FILTRATION RATE USING BLOOD CYSTATIN-C 01 Turn Device On 02 Connect Bluetooth 03 Draw Sample 04 Insert Sample into Cartridge 05 Open Lid 06 Insert Cartridge 07 Close Lid 08 Wait for Test Completion 09 Read Result
Slide 12: IP Strategy
IP STRATEGY IP PATENT EXPANSION FOR: CYS-C Chip New Cartridge Design for Fluid Handling Optical Reader Design UC Chip Trademarks for MATLOC 1(ACR) and MATLOC2(ACR + GFR) We are pursuing an IP Strategy around New Method and New Design Intellectual Property to build an IP fence around MATLOC 2 and fut
Slide 13: Expected Patient Journey
EXPECTED PATIENT JOURNEY* Home Testing Device Web Portal DATA COLLECTION SIGN UP ASSESSMENT DEVICE DATA COMPLIANCE ▪ Name, age, gender, email, mobile # ▪ Risk & symptom survey ▪ Device output ▪ HIPAA compliant ▪ Current HCP info, purpose ▪ DX data, treatment plan ▪ Phone sensor data ▪ Social (FB) ge
Slide 14: Smartphone Experience
SMARTPHONE EXPERIENCE Confidential 14
Slide 15: Potential Revenue Channels
POTENTIAL REVENUE CHANNELS* OUR BUSINESS CUSTOMERS OUR PATIENTS (80 MILLION AT RISK OF DEVELOPING CKD) (1) RURAL COMMUNITIES: DIABETEC PATIENTS: (**) 20% of the US population. Lack of access to • Make up 45% of all CKD cases • 1.1 million new diagnosis every year healthcare necessitates point of car
Slide 16: Competitive Analysis
COMPETITIVE ANALYSIS How compares My Health Logic* Healthy IO** DCA Vantage** Roche Cobas** Low-Cost Handheld Precise Quantitative Available for Home-Use Digital Connectivity eGFR Capabilities (In Development) • Forward-looking statement. See “Disclaimer: Forward-Looking Statements” and “Risk Factor
Slide 17: Technology Timeline
TECHNOLOGY TIMELINE* KEY DATES WITH THE FOCUS ON MATLOC 1 AND MATLOC 2: MATLOC 1 MATLOC 2 POC UACR Lab-on-Chip Quantitative Measurement Device for urine albumin - to - POC CYS-C Lab-on-Chip Quantitative Measurement Device for Glomerular Filtration creatinine ratio (ACR) as an aid for diagnosis of Ch
Slide 18: Market Comparables
MARKET COMPARABLES Livongo (NASDAQ: LVGO) Dario Health (NASDAQ: DRIO) Renalytix (NASDAQ: RNLX) Market cap: Merged with Teladoc (TDOC) Market cap: $360 million US Market cap: $1.15 billion US at $18.5 billion USD valuation A digital health company focused on Provides personalized health management Di
Slide 19: Team Bios
TEAM BIOS LEADERSHIP TEAM David Barthel, MBA, CEO Braeden Lichti, Co-Founder ▪ Over 20 years as founder and executive leader in the healthcare and medical device space ▪ Over 12 years of experience in direct investing and venture building with a focus on ▪ Raised over $70m in venture funding the lif
Slide 20: Team Bios
TEAM BIOS CAPITAL MARKETS TEAM George Kovalyov, CPA, COO, Director Harrison Ross, CFA, CFO, Director ▪ Over 15 years experience as CPA, financial controller for both private and public companies ▪ Over 7 years of financial management and analyst experience in both private and public ▪ Vice President
Slide 21: Thank You
THANK YOU Harrison Ross 877-456-4424 harrison@healthlogicinteractive.com
Slide 22: References
REFERENCES [1] “The Dawn of Digital Medicine,” The Economist, Dec. 03, 2020. https://www.economist.com/business/2020/12/02/the-dawn-of-digital-medicine. [2] “Digital Patient Monitoring Devices Market Worth $446.0 Billion By 2028,” Grand View Research, Jun. 2021. https://www.grandviewresearch.com/pre
Slide 23: Risk Factors
RISK FACTORS RISK FACTORS When used in this Risk Factors section, references to the “Company”, “we”, “our” or “us” refer to Health Logic Interactive Inc. and its affiliates. The following are certain factors relating to the business of the Company. These risks and uncertainties are not the only ones
Slide 24: Risk Factors (continued)
RISK FACTORS (CONTINUED) General healthcare regulation Healthcare service providers in Canada are subject to various governmental regulation and licensing requirements and, as a result, the Company’s businesses operate in an environment in which government regulations and funding play a key role. Th
Slide 25: Risk Factors (continued)
RISK FACTORS (CONTINUED) Uninsurable risks The medical business is subject to several risks that could result in damage to or destruction of properties or facilities or cause personal injury or death, environmental damage, delays in production and monetary losses and possible legal liability. It is
Health Logic Interactive — Investor Presentation (June 2021) on 6ix